The short answer
Magnesium matters when used as an antacid. Keep it at least two hours before or after dasatinib according to the oral product instructions, and confirm the actual formulation with the pharmacist.
What this answer covers
Oral dasatinib and magnesium in an acid-neutralizing antacid. Nutritional salts without equivalent antacid activity are not automatically the same exposure.
- Supplement or preparation
- Magnesium
- Medication ingredient
- dasatinib
Check the exact treatment
This review concerns oral dasatinib tablets. Conventional tablets and PHYRAGO contain the same active ingredient but can differ in their response to acid-reducing medicines. Keep the exact prescribed product and have its directions checked before changing a supplement or antacid.
Identify the product’s purpose
The concern is reduced drug availability when an antacid changes the stomach environment. Magnesium on a nutrition label alone does not establish an antacid dose or acid-neutralizing effect. Check the salt, strength and whether it is sold for indigestion, mineral replacement or another purpose.
What the original study measured
A volunteer study found much lower dasatinib exposure when an aluminum/magnesium hydroxide antacid was taken together with the drug. Giving that mixture two hours earlier avoided a relevant change in total exposure. The result does not quantify the effect of every mineral salt.
Keep the timing and formulation together
For both conventional dasatinib tablets and PHYRAGO, antacids need at least two hours of separation. PHYRAGO reports different findings with certain longer-acting acid reducers, so those findings should not be applied to another dasatinib formulation. Do not switch products or acid medicines yourself.
Evidence and practical considerations
Timing & monitoring
The current exact oral instructions support a preparation-specific antacid interval rather than a blanket interaction with every mineral supplement.
- Exact scope
- Oral dasatinib and magnesium in an acid-neutralizing antacid. Nutritional salts without equivalent antacid activity are not automatically the same exposure. with RxNorm 475342 IN dasatinib. Current exact oral product: Dasatinib oral monohydrate tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- Exact oral antacid instruction; no universal mineral binding effect or salt-specific cancer-outcome evidence. PHYRAGO acid-reducer findings differ from conventional formulation; antacid spacing retained for both.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Antacids two hours apart; avoid strong CYP3A inducers; bleeding and thrombocytopenia warnings.
How this applies: RxNorm 475342 IN dasatinib. Current exact oral product: Dasatinib oral monohydrate tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 24 healthy volunteers in crossover.
Simultaneous antacid reduced exposure 55–58%; two-hour prior administration did not change total exposure.
How this applies: Exact reported preparation, population and endpoints; transfer to dasatinib explicitly limited.
Abstract-only specific mixture, not every mineral supplement or calcium salt. No clinical response endpoint.
Source 3: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed PHYRAGO.
Antacid at least two hours before/after; no clinically significant omeprazole/famotidine PK difference reported.
How this applies: Exact ingredient with explicit formulation boundary.
Formulation-specific findings; no transfer of H2/PPI null result to conventional dasatinib.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
dasatinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 352a170f09a6c39e
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.